ProMPT (Prostate Cancer: Mechanisms of Progression and Treatment)

Lead Research Organisation: University of Cambridge
Department Name: Oncology

Abstract

Members of our group are actively involved with a number of external stakeholders including the Department of Health (England), the HEFCE and major national charities and scientific societies. We regularly report in the media on prostate cancer matters of topical interest and have actively influenced UK Health Policy with respect to screening, configuration of services for men with prostate cancer, quality control with respect to surgical and radio-therapeutic treatments, and prostate biopsy. Each of the clinically active members has regular interaction with local and national patient groups for prostate cancer

Technical Summary

ProMPT is a collaborative translational research group based in six UK universities studying advanced and progressing prostate cancer. Our aims are to study the molecular pathology of hormone resistant and metastatic prostate cancer in man to identify potential targets, which we are studying and validating in human tissue and human cell models that we have developed. Our drug development and bio-repository programmes both ensure that we constantly focus on potential benefit to patients. The main bio-science discovery programmes, focused on advanced or progressing disease feed forward into translational studies. Our clinical studies are focused on testing novel agents accompanied by laboratory investigation of biopies to determine the effects on prostate cancer. The rapidly developing genetic epidemiology group is carrying out studies which aim to identify high risk groups and potentially modifiable environmental agents. There is active management, regular workshops and meetings to ensure that the potential added value of the collaborative is realised.

Publications

10 25 50
 
Description Manchester - Noel Clarke - Advisor HTA/NICE
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact n/a
 
Description Manchester - Noel Clarke - Chair EORTC GU Group Prostate DOG
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact n/a
 
Description Manchester - Noel Clarke - Chair NCRI Prostate CSG 03-09
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact n/a
 
Description Manchester - Noel Clarke - Member of Dept of Health Prostate Cancer Advisory Board
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact n/a
 
Description Manchester - Noel Clarke - Member of Scientific Advisory Board Prostate Cancer Charity
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact n/a
 
Description Manchester - Noel Clarke - Scientific Advisor Prostate UK
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact n/a
 
Description National Steering Committee for Prostate Cancer
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Members of ProMPT continue to have major impact on national policy. Professor Hamdy and Professor Donovan sit on the National Steering Committee for Prostate Cancer.
 
Description Oxford - Freddie Hamdy - NICE Guidelines
Geographic Reach National 
Policy Influence Type Membership of a guidance committee
Impact n/a
 
Description Prostate Cancer Action Group of the Dept of Health
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact Professor Neal and Professor Cooper from the ICR sit on Prostate Cancer Action Group of the Dept of Health and Professor Neal has recently been appointed to be Vice Chair of the Prostate Cancer Action Group working with Dr Mike Richards.
 
Description ProtecT Study
Geographic Reach National 
Policy Influence Type Participation in a national consultation
Impact The ProtecT Study will determine NHS policy when it is published after 2015.
 
Description York - Norman Maitland - MRC College of Experts
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact n/a
 
Description prostate cancer advisory group
Geographic Reach National 
Policy Influence Type Participation in advisory committee
Impact several policy documents from DoH inluding brachytherapy policy
 
Description Anthropometric markers of childhood nutrician and cancer
Amount £74,974 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start  
 
Description Association of circulating vitamin D metabolite levels with incidence and progression of screen detected prosate cancer
Amount £149,367 (GBP)
Funding ID 2007/07 
Organisation World Cancer Research Fund 
Sector Charity/Non Profit
Country Global
Start  
 
Description Association of factors in the folate metabolic pathway with prostate cancer incidence and progression
Amount £147,971 (GBP)
Funding ID 2006/15 
Organisation World Cancer Research Fund 
Sector Charity/Non Profit
Country Global
Start  
 
Description AstraZeneca (Endothelin-1 and Statin Blockade of Prostate Bone Metastasis)
Amount £349,672 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start  
 
Description Biomarker discovery using proteomic approaches in urological tumours
Amount £187,000 (GBP)
Organisation Koninklijke Philips Electronics N.V. 
Department Philips
Sector Private
Country Global
Start 07/2007 
End 12/2012
 
Description Bristol University Cancer Research Committee (Identification of a role for Adipokines in prostate cancer progression)
Amount £4,985 (GBP)
Organisation University of Bristol 
Sector Academic/University
Country United Kingdom
Start  
 
Description CRUK Graduate Training Fellowship in Cancer Public Health and Epidemiology
Amount £53,782 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description CRUK Programme Grant (Translational Research in Prostate Cancer)
Amount £800,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2006 
End 03/2010
 
Description CRUK funding (A Whole Genome association study to identify common susceptibiltiy alleles for prostate cancer)
Amount £4,000,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
End 11/2009
 
Description CRUK funding (The IGF system in prostate cancer aetiology and prognosis a large population based cohort study)
Amount £424,054 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2007 
End 12/2009
 
Description CRUk funding (The feasibility of a randomised controlled trial of dietary interventions for men at high risk of prostate cancer)
Amount £40,071 (GBP)
Funding ID C11046/A10052 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2009 
End 09/2010
 
Description Cambridge - CANCURE (2m euros across 11 participants)
Amount £188,564 (GBP)
Funding ID 20970 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 07/2006 
End 06/2010
 
Description Cambridge - CRUK TRICC
Amount £525,098 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2010 
End 12/2012
 
Description Cambridge/Bristol/Oxford - NIHR, HTA, ProtecT
Amount £13,700,000 (GBP)
Organisation National Institute for Health Research 
Department Health Technology Assessment Programme (HTA)
Sector Public
Country United Kingdom
Start 01/2009 
End 12/2013
 
Description Christie Hospital Research Endowments, Study of Metastatic and cancer stem cell behaviour in prostate and renal cancer
Amount £158,493 (GBP)
Organisation Christie Hospital Research Endowments 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Effects of Proneural Transcription Factors in Hormone Refractory Disease
Amount £25,000 (GBP)
Organisation Prostate Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Equipment grant for a Varian 670-IR spectrometer coupled to a Varian 620-IR Scope
Amount £157,000 (GBP)
Organisation Age UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Lipid signalling in site directed prostate cancer metastasis. Faculty of Medical and Human Sciences - 2007 School of Medicine Strategic PhD Studentship
Amount £48,000 (GBP)
Organisation University of Cambridge 
Sector Academic/University
Country United Kingdom
Start  
 
Description Novel proteomic approach combined with an RNAi screen to identify AR co factors
Amount £26,000 (GBP)
Funding ID 110853 
Organisation Prostate Cancer UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description PROMARK Genetic prostate cancer variants as biomarkers of disease progression (2.7m euros across 6 participants)
Amount £400,000 (GBP)
Funding ID 202059 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 01/2008 
End 12/2012
 
Description Sheffield - ProsPER Prostate cancer: profiling and evaluation of ncRNA (3m euros across 8 participants)
Amount £406,500 (GBP)
Funding ID 201438 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 02/2008 
End 07/2012
 
Title Affymetrix database 
Description 5. Affymetrix mirco-array database of prostatic SP subpopulations from normal, benign and malignant human tissue 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact N/A 
 
Title Bone Marrow Stroma co-culture models 
Description 1. Bone Marrow Stroma co-culture models of a. Transendothelial migration b. Invasion c. Metastatic colony formation d. Chemotherapeutic intervention 
Type Of Material Model of mechanisms or symptoms - human 
Provided To Others? No  
Impact N/A 
 
Title Chemometric (FTIR) Grading and Staging of Prostatic Tissue 
Description Chemometric (FTIR) Grading and Staging of Prostatic Tissue 
Type Of Material Physiological assessment or outcome measure 
Provided To Others? No  
Impact N/A 
 
Title Chromatin immunoprecipitation methods 
Description Methods of carrying out chromatine immunoprecipitation in prostate cells have now been published and a paper has been prepared doing the same for chromatine immunoprecipitation and high through put sequencing which is ready to go as a paper for androgen receptor function. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact SEE PAPERS BY MASSIE AND MILLS 
 
Title Isolation of prostatic epithelial side populations (SP) 
Description 2. Isolation of prostatic epithelial side populations (SP) from benign and malignant human tissue 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact N/A 
 
Title New joint ProMPT/Southern Collaborative Database 
Description A new joint database has been established between Professor Cooper and Professor Neal and Professor Hamdy in Oxford to deal with the large amount of scientific data that is now coming through from Human bio materials. 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact n/a 
 
Title Newcastle - Plasmids 
Description Plasmids created within this project have been made freely available to the research community. Multiple requests have been made from international research groups and products shipped as required. 
Type Of Material Technology assay or reagent 
Year Produced 2006 
Provided To Others? Yes  
Impact n/a 
 
Title ProMPT 
Description Databases have been established for ProMPT (Dr Rajeev Kumar Sheffield/Oxford) for annotated clinical samples. 
Type Of Material Database/Collection of Data/Biological Samples 
Year Produced 2007 
Provided To Others? Yes  
Impact ONGOING PUBLICATIONS AS IN PUBLICATION LIST 
 
Title ProMPT and ProtecT bio-repository 
Description ProMPT and ProtecT biorespoitories, design and development of standard operating procedures for biobanking (attached), establishment of a processing facility using automated equipment at Oxford. 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact MANY PAPERS AS IN PUBLICATIONS LIST 
 
Title ProtecT Database 
Description Databases have been established for the clinical trail (ProtecT). 
Type Of Material Database/Collection of Data/Biological Samples 
Year Produced 2006 
Provided To Others? Yes  
Impact several high impact publications as outlined in publications 
 
Title Tissue/Serum Bank 
Description 3. Tissue/Serum Bank a. Snap Frozen Tissue b. FFPE Tissue c. Single Cell Suspensions d. Epithelial e. Fibroblast f. Serum 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact N/A 
 
Title York - 50 Cancer cultures established and banked 
Description The major aim of our NCRI funded research was to (i) increase the pool of prostate cancer stem cell cultures available for molecular analyses and (ii) to optimise xenografting conditions for prostate tissues and stem cell derived cultures. More than 50 cancer cultures have been established and banked. It is clear that these cultures change with time in culture and the availability of larger numbers of truly primary cultures from human material which share the phenotype with the original tissues, for example by expression of the TMPRSS2-ERG fusion (which is lost on prolonged culture). Optimised xenografting conditions remain difficult to achieve. However we now have 4 serially passaged xenografts from which stem cells can be retrieved. One culture has been passages 19 times in vivo. A unique feature of this resource is the frequency and location of the observed metastases from a renal capsule or even a subcutaneous implant. 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact n/a 
 
Title York - annotated catalogue of genes 
Description As an extension of the previous grant we have now expanded and published in public data bases an annotated catalogue of genes (based on the Affymetrix plus 2 human chip) expressed in various differentiated cell types in prostate and prostate cancer (Arrayexpress). 
Type Of Material Database/Collection of Data/Biological Samples 
Provided To Others? No  
Impact n/a 
 
Description Bone turnover and PSA Isoforms 
Organisation F. Hoffmann-La Roche AG
Department Roche Diagnostics
Country Global 
Sector Private 
PI Contribution Collaboration with Roche Diagnostics (Dr Nicholas Hoyle, Penzberg, Germany), and Memorial Sloan Kettering Cancer Centre (Dr Hans Lilja, New York, USA) to evaluate markers of bone turnover and PSA isoforms in predicting disease progression and metastases in prostate cancer. Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.
Impact Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.
Start Year 2007
 
Description Bone turnover and PSA Isoforms 
Organisation Memorial Sloan Kettering Cancer Center
Country United States 
Sector Academic/University 
PI Contribution Collaboration with Roche Diagnostics (Dr Nicholas Hoyle, Penzberg, Germany), and Memorial Sloan Kettering Cancer Centre (Dr Hans Lilja, New York, USA) to evaluate markers of bone turnover and PSA isoforms in predicting disease progression and metastases in prostate cancer. Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.
Impact Output: MD Thesis (Mr Joshua Philips - viva on 10 Dec 2009), paper in preparation.
Start Year 2007
 
Description ERK5 
Organisation Newcastle University
Department Northern Institute for Cancer Research Newcastle
Country United Kingdom 
Sector Academic/University 
PI Contribution ERK5 project - Newcastle University Drug Development Group and Cancer Research Technology - ongoing drug development programme. Added value - post-doctoral researcher from CRT to develop biologic markers downstream of ERK5. PhD student from Newcastle CR UK drug development programme to work on ERK5 targetting molecules.
Impact See Darby et al, 2009
Start Year 2007
 
Description GWS 
Organisation Cancer Research UK
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.
Collaborator Contribution We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.
Impact See publications: Eeles et al, 2008 and 2009; Al Olami et al 2009; and Ghoussaini et al 2008; 3 Nature Genetics and 1 JNCI paper
Start Year 2007
 
Description GWS 
Organisation University of Cambridge
Department Department of Public Health and Primary Care
Country United Kingdom 
Sector Academic/University 
PI Contribution We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.
Collaborator Contribution We also have an exciting collaboration with Professor Ros Eeles at the Institute of Cancer Research, Professor Doug Easton at the Strangeways Laboratory and Professor Paul Pharaoh and Dr Nora Pashayan carrying out studies of genome wide scanning in prostate cancer. Using the bio-repository which has been partly funded by ProMPT this has led to the discovery of a large number of novel pre-disposition alleles and has led to four major publications - three in Nature Genetics and one in the JNCI. The ProMPT collaborative itself continues with its internal collaborations and these include joint clinical studies between Bristol, Sheffield (now Oxford) and Cambridge coupled with a well annotated bio-repository from ProtecT. The bio materials are kept in Oxford and Cambridge and the database is managed through a large clinical trial database in Bristol.
Impact See previous papers: Eeles et al, 2008; 2009; Ghoussaini et al 2008 and Al Olami et al 2009.
Start Year 2007
 
Description Sprouty2 
Organisation National University of Singapore
Country Singapore 
Sector Academic/University 
PI Contribution Sprouty2 - collaboration with Professor Graeme Guy, Singapore
Impact see Darby et al 2009
Start Year 2007
 
Title ERK5 
Description A successful ERK5 project will delivery a clinical candidate in 2-3 years. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Initial development
Year Development Stage Completed 2010
Development Status Under active development/distribution
Impact see 9.6 
 
Title phospho-p68 antibodies 
Description We are developing mouse monoclonal phospho-p68 antibodies to detect activated p68 in clinical material. These antibodies may be more useful than the commercially available p68 antibodies to detect changes in prostate cancer patients with disease progression. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Initial development
Year Development Stage Completed 2010
Development Status Under active development/distribution
Impact n/a 
 
Company Name Pro-Cure Therapeutics Ltd 
Description Pro-Cure Therapeutics has now raised around £3M over the last 4 years, and most recently a final seed round of £700,000 in the last month. It has 10 scientists and a small admin and marketing staff. ; http://www.pro-cure.uk.com/ 
Year Established 2006 
Impact Negotiation for alliances with major Pharma companies in the Stem cell field are at an advanced stage, and bids for large scale VC funding for preclinical and clinical studies have passed an initial due diligence. Two research collaborations with International Pharma have already been completed.
Website http://www.pro-cure.uk.com/
 
Description Cambridge - various presentations to patients organisations and schools 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact A number of presentations and publications have been made together with presentations at Department of Health meetings and NCRI meetings where there are non-academic audiences. In particular, these included a number of new interviews with national papers carried out by Professor Neal and visits to the House of Commons to talk to various scientific committees in connection with prostate translational research. One of these was organised by Cancer Research UK at which Professor Colin Cooper, Professor David Neal spoke to MPs and others in the House of Commons.

n/a
Year(s) Of Engagement Activity 2009
 
Description Cambridge - videos of operative procedures 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact A number of videos have been made of operative procedures for men with prostate cancer and these have led to features in national newspapers including the Times with a website download of operations being carried out.

videos on BBC and Times websites
Year(s) Of Engagement Activity 2008
 
Description Glasgow - Open Day 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Speaking to open day at the Cancer Research UK Beatson Institute for Cancer Research.

n/a
Year(s) Of Engagement Activity 2008,2009
 
Description Manchester - various lectures 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact British Urological Group 2008: Influence of NICE Guidance on Prostate Cancer in the UK 2009: Prostate Cancer Screening British Association of Urological Surgeons 2008: Influence of NICE Guidance on Prostate Cancer in the UK 2009: Use and Timing of Androgen Deprivation in Prostate Cancer British Association of Urological Nurses 2008 The management of hormone refractory prostate cancer Royal College of Physicians 2008 Emerging trends in Urological Oncology Royal College of Physicians London Uro-Oncology Update 2009 The use of 5a Reductase Inhibitors in prostate cancer prevention European Society of Oncological Urology Berlin 2008: Use of Molecular Biomarkers in Prostate Cancer What does PSA failure after radiation or surgery mean European Association of Urology Annual Congress Milan 2008 Pathophysiology of Bone Metastasis in Prostate Cancer European Association of Urology Annual Congress Stockholm 2009 GnRH Antagonists and Hormone Manipulation in Prostate Cancer European Multi-Disciplinary Meeting on Urological Cancer Barcelona 2009 RANK Ligand Inhibition in Prostate Cancer Nikei University Tokyo 2008 Mechanisms of metastatic spread in prostate cancer Japanese Association of Urology 2009 The European Association of Urology Lecture: The Management of Castrate Resistant Prostate Cancer Belgian Association of Urology 2009 RANK Ligand Inhibitors in the management of Metastatic Bone Disease from Prostate Cancer Spanish National Urology Course Institut Juan Puigvert 2009 Isolation and Characterisation of Prostate cancer stem cells using Hoescht 33342 extraction Novel imaging in Prostate Cancer Malmo University 2008 Mechanisms of metastatic spread in prostate cancer Prostate Cancer Support Federation 2009 What is the Importance of Research in Prostate Cancer ? Prostate Cancer UK 2008 The management of advanced prostate cancer The Royal College of Radiologists 2008 Does the surgeon need more or less radiology

n/a
Year(s) Of Engagement Activity 2008,2009
 
Description Newcastle - NICR Outreach 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Primary Audience Schools
Results and Impact The NICR has a full-time local engagement and development (LEAD) manager funded by CR UK and we operate both outreach (to schools and the local community) and invite members of the public to regular open days in our Institute. Presentations from the Principal investigators include talks at local schools, to teachers and to several organised charity events.

n/a
Year(s) Of Engagement Activity 2006,2007,2008,2009
 
Description York - Laboratory Open Evenings 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact At least 3 laboratory open evenings per year when either 3-4 graduate students or younger postdocs give 15 minute talks and a conducted tour of our facilities.

n/a
Year(s) Of Engagement Activity 2008,2009
 
Description York - Regular presentations 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Primary Audience Participants in your research and patient groups
Results and Impact Regular presentations (using and quoting the NCRI badge) to charity collectors, prostate cancer patient support groups and University of the Third Age . Talks not only in York but in Merseyside, Hull, Leeds and London (Royal Society of Medicine).

n/a
Year(s) Of Engagement Activity 2008,2009